Table 2.
Clinical trials evaluating the accuracy of TAD for axillary staging in patients with initially metastatic axillary lymph nodes undergoing NACT
| Trial | N | Tumor stage | Marking/localization method TLN | FNR, % |
|---|---|---|---|---|
| Boughey et al. [64] Ann Surg 2016 (ACOSOG Z1071) | 107 | T0–T4, N1–N2 | Clip | 6.8 |
| Caudle et al. [68] JCO 2016 | 85 | T0–T4, N1–N2 | Clip/iodine seed | 2 |
| Siso et al. [69] Ann Surg Oncol 2018 (ILINA) | 35 | T1–T4, N1–N2 | Clip/IOUS | 4.1 |
| Simons et al. [69] (RISAS) | 227 | T1–T4, N1–N2 | Iodine seed | 3.5 |
| Hartmann et al. [70] BJS 2021 (TATTOO) | 110 | Stadium I–IV, N1–N3 | Carbon | 9 |
| Boniface et al. [71] Breast Cancer Res Treat. 2022 (extended TATTOO) | 149 | T1–T4, N1–N3 | Carbon | 6.2 |
| Renaudeau et al. [72] SABCS 22-OT1 09-01 (GANEA3) | 260 | T1–T4c, N1–N3 | Clip | 6 |
| Kuemmel et al. [73] Ann Surg 2022 (SENTA) | 77 | T1–T4c, N+ | Clip | 4.3 |